Attorney Docket No.: 10499.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al

Confirmation No: TBA

Serial No.: TBA

Group Art Unit: TBA

Filed: April 19, 2006

Examiner: TBA

ا .

For: Carbohydrate-Binding Modules of a New Family

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: April 19, 2006

Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600

New York, NY 10110

(212) 840-0097

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap	erwork Reduction /	<u> Act of 1995, no per</u>	sons are required to	respond to a collection of information unles	s it contains a valid OMB control numb	er.		
Substitute for form 1449A/PTO				Compl	Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	TBA 10/5	フムトクロ		
				Filing Date				
				First Named Inventor	Schnorr et al			
				Art Unit	TBA			
				Examiner Name	TBA			
Sheet	1	of	2	Attorney Docket Number	10499.204-US			

		U.	S PATENT DOCU	MENTS	
Examiner Initials	Cite No. 1	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	-				· · · · · · · · · · · · · · · · · · ·
					
 					
					-
	-				
					· · · · · · · · · · · · · · · · · · ·
		1			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т 6	
		WO 03/000941	01-03-2003	Novozymes A/S			
		WO 03/044049	05-30-2003	Novozymes A/S			
-	-						
				-			
	ļ <u>.</u>						
		(= 10)					
					<u>-</u> .	—	
	ļ					—	
	ļ		ļ			-	
							
	 						
							
	-		-			 	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Compl	Complete if Known			
				Application Number	TBA 11/2/0			
	INFORMAT	ION DISCLOSI	JRE	Filing Date	April 19, 2006			
STATEMENT BY APPLICANT				First Named Inventor	Schnorr et al			
(use as many sheets as necessary)			y)	Art Unit	TBA			
				Examiner Name	TBA			
Sheet	2	of	2	Attorney Docket Number	10499.204-US			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T 2		
		Coutinho et al., Recent Advances in Carbohydrate Bioengineering, "Carbohydrate-Active Enzymes: An Integrated Database Approach", pp.3-12 (1999)			
		Bourne et a., Carbohydrates and Glycoconjugates, "Glycoside Hydrolases and Glycosyltransferases: families and functional modules", pp. 593-600 (2001)			
		Levy et al., Biotechnology Advances, Vol. 20, pp. 191-213 (2002)			
		Blume et al., The Journal of Biological Chemistry, Vol. 266, No. 23, pp.15432-15437 (1991)			
	-				

Examiner	Date	=
Signature	Considered	·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

528

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.